Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
SANOFI	75017 PARIS

International Classification(s)

• A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
• C07C:ACYCLIC OR CARBOCYCLIC COMPOUNDS

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
BRITTAIN, Jason	El Cajon, US	4	0
# of filed Patents : 4 Total Citations : 0
PERNERSTORFER, Josef	Paris, FR	50	530
# of filed Patents : 50 Total Citations : 530
ROCCO, William	Reading, US	5	4
# of filed Patents : 5 Total Citations : 4

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 0 Citation Count
• A61K Class

• 0 % this patent is cited more than
• 3 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
3.5 Year Payment	$1600.00	$800.00	$400.00	Sep 3, 2025
7.5 Year Payment	$3600.00	$1800.00	$900.00	Sep 3, 2029
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Sep 3, 2033

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 3.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2022/0064,105

CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING

---

Abstract

---

Described herein are crystalline forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid and methods of making the same. Such forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid are useful in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with an EDG-2 receptor antagonist compound.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.